書籍詳細

Part 1 北海道・東北地区

P.26 掲載の参考文献

• 1) 間部克裕, 高橋美香子, 大泉晴史ほか, 山形県臨床 Helicobacter pylori 研究会:山形県におけるHelicobacter pylori 除菌療法の現状と問題点. Helicobacter Research 8:176-184, 2004

• 2) 間部克裕, 高橋美香子, 深瀬洋子ほか:クラリスロマイシンの用量が除菌率および副作用に及ぼす影響-山形県臨床 Helicobacter pylori 研究登録制度による検討-. 新薬と臨床 52:740-745, 2003

• 3) 間部克裕, 大泉晴史, 門馬孝ほか, 山形県臨床 Helicobacter Pylori 研究会:Helicobacter Pylori 再除菌治療の検討. 新薬と臨床 54:1003-1009, 2005
  Medical*Online

• 4) 間部克裕, 深瀬和利, 安藤雅美ほか:Helicobacter Pylori 除菌判定における尿素呼気試験の偽陽性についての検討. 山形県立病院医学雑誌 38:10-13, 2004

• 5) 間部克裕, 北澤利彦, 加藤智恵子ほか:尿素呼気試験における偽陽性の原因. Helicobacter Research 8:50-54, 2004
  Medical*Online

P.31 掲載の参考文献

• 1) Sharma VK, Sahal AV, Corder FA et al:Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent futher ulcer hemorrhage. Aliment Pharmacol Ther 15:1939-1947, 2001

• 2) Ohara S, Kato M, Asaka M et al:Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 33:6-13, 1998
  pubmed

• 3) 大原正志, 野口光徳, 浅木茂:ヘリコバクターピロリ陰性潰瘍の粘膜免疫. Helicobacter Research 2:334-339, 1998

Part 2 関東地区

P.47 掲載の参考文献

• 高橋信一:これでわかるピロリ除菌療法と保険適用-ガイドラインに基づく活用法-改訂版, 南江堂, 2004

Part 3 信越・北陸・東海地区

P.62 掲載の参考文献

• 1) 須田陽子, 佐藤正之, 村川英三ほか:化学療法後に根治的胃全摘術を施行した進行型胃原発性悪性リンパ腫の1例. 臨床血液 25:1881, 1984

• 2) 加藤俊幸, 秋山修宏, 船越和博ほか:胃悪性リンパ腫における化学療法の効果判定と予後. 胃と腸 33:447-456, 1998

• 3) 梨本篤, 佐々木壽英, 田中乙雄ほか:胃悪性リンパ腫-neoadjuvant化学療法症例を中心に-. 消化器内視鏡 11:1525-1536, 1995

• 4) 加藤俊幸, 秋山修宏, 本山展隆ほか:長期予後からみた胃悪性リンパ腫の非手術的治療の選択と経過観察. 消化器科 38:59-66, 2004

• 5) 小越和栄, 丹羽正之, 斉藤征史ほか:良性リンパ腫. 総合臨床 34:1537, 1985

• 6) 山下浩子, 味岡洋一, 渡辺英伸ほか:胃MALTリンパ腫におけるH. Pylori除菌治療後の経過. 胃と腸 34:1389-1396, 1999

• 7) 加藤俊幸:胃のリンパ腫, MALToma, RLH. 今日の消化器疾患治療指針 2版, 多賀須幸男ほか編, 医学書院, 東京, 2002, pp413-415

• 8) 加藤俊幸, 小越和栄, 秋山修宏ほか:胃MALTリンパ腫におけるH. Pylori除菌治療の効果とその後の経過. 胃と腸 34:1345-1352, 1999

• 9) 加藤俊幸, 小越和栄, 秋山修宏ほか:胃MALTリンパ腫の除菌後の化学療法と放射線療法. 消化器科 30:304-309, 2000

• 10) 加藤俊幸, 秋山修宏, 本山展隆:胃MALT Lymphoma-除菌で消退する内視鏡像から遺伝子解析へ. ENDOSCOPIC FORUM for digestive disease 18:178-183, 2002
  Medical*Online

• 11) 加藤俊幸:胃癌の診断と治療-最新の研究の動向-;胃MALTリンパ腫. 日本臨牀 59 (suppl 4):S267-S271, 2001

Part 4 近畿地区

P.82 掲載の参考文献

• 1) 徳永健吾, 高橋信一:保険診療下の Helicobacter Pylori:非侵襲的診断法選択の実際. Helicobacter Research 9:13-19, 2005
  Medical*Online

Part 5 中国・四国地区

P.94 掲載の参考文献

• 1) Warren JR, Marshall BJ:Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lanceti:1273-1275, 1983

• 2) Kawaguchi H, Haruma K, Komoto K et al:Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 91:959-962, 1996
  pubmed

• 3) Komoto K, Haruma K, Kamada T et al:Helicobacter pylori infection and gastric neoplasia:correlations with histological gastritis and tumor histology. Am J Gastroenterol 93:1271-1276, 1998
  pubmed

• 4) Lind T, Veldhuyzen van Zanten S, Unge P et al:Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials:the MACH I Study. Helicobacter 1:138-144, 1996

• 5) van der Hulst RWM, Rauws EAJ, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:A prospective long-term follow-up study. Gastroenterology 113:1082-1086, 1997

• 6) Treiber G, Lambert JR:The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 93:1080-1084, 1998
  pubmed

• 7) Leodolter A, Kulig M, Brasch H et al:A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 15:1949-1958, 2001
  pubmed

• 8) 鎌田智有, 春間賢, 吉原正治ほか:Helicobacter pylori除菌後の背景胃粘膜の性状と潰瘍の再発. 胃と腸 35:637-646, 2000

• 9) Kamada T, Haruma K, Komoto K et al:Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 4:204-210, 1999
  pubmed

• 10) Kamada T, Haruma K, Miyoshi E et al:Cetraxate, a mucosal protective agent, combined with omeprazole, amoxicillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 14:1089-1094, 2000
  pubmed

• 11) Masuda H, Hiyama T, Yoshihara M et al:Characteristics and trends of clarithromycin-resistant Helicobacter pylori isolates in Japan over a decade. Pathobiology 71:159-163, 2004

• 12) Hamada H, Haruma K, Mihara M et al:High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori:impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 14:729-735, 2000
  pubmed

• 13) Sasaki A Haruma K, Manabe N et al:Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 17:1529-1534, 2003
  pubmed

P.106 掲載の参考文献

• 1) 洲脇謹一郎, 池田宣聖, 三宅康弘ほか:Dry Syrupを用いたHelicobacter pylori 除菌治療の検討. 三豊総合病院雑誌 17:3, 1996

• 2) 洲脇謹一郎, 中津守人, 稲葉知己ほか:保険認可後に予想されるHelicobacter Pylori (HP) 除菌治療の問題点-治療期間は1週間がBestか. 日本消化器病学会雑誌 98:A208, 2001

• 3) Lamouliatte H, Forestier S, Perie F et al:Lansoprazole (Lanso) 30mg or 60mg combined with two Antibiotics[Amoxicillin (Amox) and Clarithromycin (Clari) ]to eradicate Helicobacter pylori. Gastroenterology 114 (A194):4, 1998

Part 6 九州・沖縄地区

P.111 掲載の参考文献

• 1) Isomoto H, Furusu H, Morikawa T et al:5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 14:1619-1623, 2000
  pubmed

P.119 掲載の参考文献

• 1) 藤岡利生, 児玉雅明, 香川二朗ほか:ヘリコバクター・ピロリ感染症. 日本臨牀 61 (suppl 2):443-449, 2003

• 2) EBMに基づく胃潰瘍診療ガイドライン, 科学的根拠に基づく胃潰瘍診療ガイドラインの策定に関する研究班編, じほう, 2003

• 3) 佐藤俊三, 阿部寿徳, 平林康宏ほか:H. Pylori除菌後に吐血をきたした十二指腸潰瘍再発の1例. 臨床医 27:79-82, 2001

• 4) 村上和成, 沖本忠義, 佐藤竜吾ほか:わが国における薬剤耐性菌の現状とその問題点. Helicobacter Research 7:10-13, 2003

• 5) Murakami K, Sato R, Okimoto T et al:Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16:1933-1938, 2002

• 6) 日本ヘリコバクター学会ガイドライン作成委員会:H. Pylori 感染の診断と治療のガイドライン2003年改訂版. 日本ヘリコバクター学会誌 4 (suppl 1):2-16, 2003

P.124 掲載の参考文献

• 1) 赤嶺弘:H. pyloriの除菌療法について. 沖縄医報 37 (7):43-49, 2001

• 2) 石原淳:当院における平成13・14年H. Pylori 除菌療法の集計結果について, 沖縄消化器内視鏡会学術講演会, 2003年2月 (那覇)

• 3) 宮里史郎:当院における二次除菌について, 沖縄消化器内視鏡会学術講演会, 2004年2月 (那覇)

• 4) 幸地周:当院におけるH. Pylori 除菌の成績と今後の課題について, 沖縄消化器内視鏡会学術講演会, 2003年2月 (那覇)

• 5) 平良正昭:H. pylori除菌により寛解したITPの1例, 沖縄消化器内視鏡会学術講演会, 2003年2月 (那覇)

• 6) 松茂良力:小児期H. Pylori感染症-消化器以外の関連疾患 鉄欠乏性貧血, ITPを通して-, 沖縄消化器内視鏡会学術講演会, 2004年2月 (那覇)

附録

P.130 掲載の参考文献

• 1) NIH consensus conference:Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994

• 2) The European Helicobacter pylori Study Group:Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41:8-13, 1997

• 3) Lam SK, Talley NJ:Helicobacter pylori Consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13:1-12, 1998

• 4) 日本消化器病学会 Helicobacter Pylori 治験検討委員会:Helicobacter Pylori 治験ガイドライン. 日本消化器病学会雑誌 96:169-207, 1999

• 5) Asaka M, Satoh K, Sugano K et al:Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6:177-186, 2001
  pubmed

• 6) Malfertheiner P, Megraud F, O:Morain C et al:Current concepts in the management of Helicobacter pylori infection the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 16:167-180, 2002
  pubmed

• 7) van der Hulst, Rauws EA, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:a prospective long-term follow-up study. Gastroenterology 113:1082-1086, 1997
  pubmed

• 8) Hentschel E, Brandstatter G, Dragosics B et al:Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 328:308-312, 1993
  pubmed

• 9) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 10) Asaka M, Kato M, Sugiyama T et al:Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 38:339-347, 2003
  pubmed

• 11) Chan FK, Sung JJ, Chung SC et al:Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350:975-979, 1997
  pubmed

• 12) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-iflammatory drugs in pepticulcer disease:ameta-analysis. Lancet 359:14-22, 2002

• 13) Hawkey CJ, Tulassay Z, Szczepanski L et al:Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs; HELP NSAIDs study. Lancet 352:1016-1021, 1998
  pubmed

• 14) Stolte M, Eidt S:Healing gastric MALT lymphomas by eradicating H. pylori? Lancet 342:568, 1993
  pubmed

• 15) Wotherspoon AC, Doglioni C, Diss TC et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575-577, 1993
  pubmed

• 16) Sugiyama T, Asaka M, Nakamura T et al:API 2-MALT 1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 120:1884-1885, 2001

• 17) Uemura N, Mukai T, Okamoto S et al:Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 6:639-642, 1997
  pubmed

• 18) Sung JJ, Lin SR, Ching JY et al:Atrophy and intestinal metaplasia one year after cure of H. pylori infection:a prospective, randomized study. Gastroenterology 119:7-14, 2000
  pubmed

• 19) Correa P, Fontham ET, Bravo JC et al:Chemoprevention of gastric dysplasia:randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 92:1881-1888, 2000
  pubmed

• 20) Ohkusa T, Fujiki K, Takashimizu I et al:Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern. Med 134:380-386, 2001
  pubmed

• 21) Parsonnet J, Friedman GD, Vandersteen DP et al:Helicobacter Pylori infection and risk of gastric carcinoma. N Engl J Med 325:1127-1131, 1991
  pubmed

• 22) Nomura A, Stemmermann GN, Chyou PH et al:Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325:1132-1136, 1991
  pubmed

• 23) Uemura N, Okamoto S, Yamamoto S et al:Helicobacter pylori infection and development of gastric cancer. N Engl J Med 345:784-789, 2001
  pubmed

• 24) Yamagata H, Kiyohara Y, Aoyagi K et al:Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population. Arch Intern Med 160:1962-1968, 2000

• 25) Ohkusa T, Takashimizu I, Fujiki K et al:Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter Pylori. Ann Intern Med 129:712-715, 1998
  pubmed

• 26) 菅野健太郎, 福嶋康之, 矢崎義雄ほか:Helicobacter Pylori 除菌により消失した胃過形成性ポリープの1例. Helicobacter Research 1:102-105, 1997

• 27) McColl K, Murray L, El-Omar E et al:Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 339:1869-1874, 1998
  pubmed

• 28) Blum AL, Talley NJ, O:Morain C et al:Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 339:1875-1881, 1997

• 29) Talley NJ, Janssens J, Lauritsen K et al:Eradication of Helicobacterpylori in functional dyspepsia:randomised double blind placebo controlled trial with 12 months of follow-up. Brit Med J 318:833-837, 1999

• 30) Miwa H, Hirai S, Nagahara A et al:Cure of Helicobacter pylori infection dose not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 14:317-324, 2000

• 31) Azuma T, Ito Y, Suto H et al:The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Aliment Pharmacol Ther 15:805-811, 2001

• 32) Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018-1022, 1996
  pubmed

• 33) Labenz J, Blum AL, Bayerdorffer E et al:Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442-1447, 1997
  pubmed

• 34) Befrits R, Sjostedt S, Odman B et al:Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux diseases. Helicobacter 5:202-205, 2000

• 35) Moayyedi P, Bardhan C, Young L et al:Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121:1120-1126, 2001

• 36) 杉山敏郎:H. pylori除菌後に発生するGERDは除菌が原因か?-Labenz論文の検証-. 日本ヘリコバクター学会誌 4:25-27, 2003
  Medical*Online

• 37) Gasbarrini A, Franceschi F, Tartaglione R et al:Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352:878, 1998
  pubmed

• 38) Marignani M, Angeletti S, Bordi C et al:Reversal of long-standing iron deficiency anemia after eradication of Helicobacter pylori infection. Scand J Gastroenterol 32:617-622, 1997
  pubmed

• 39) Milman N, Rosenstock S, Andersen L et al:Serum ferritin, hemoglobin, and Helicobacter pylori infection:a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology 115:268-274, 1998
  pubmed

• 40) Barabino A, Dufour C, Marino CE et al:Unexplained refractory iron-deficiency anemia associated with Helicobacter pylori gastric infection in children:further clinical evidence. J Pediatr Gastroenterol Nutr 28:116-119, 1999
  pubmed

• 41) Sugiyama T, Tsuchida M, Yokota K et al:Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection. Intern Med 41:491-494, 2002
  pubmed

• 42) Bohmeyer J, Heller A, Hartig C et al:Association of chronic urticaria with Helicobacter pylori-induced antrum gastritis. Hautarzt 47:106-108, 1996
  pubmed

• 43) Mendall MA, Goggin PM, Molineaux N et al:Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 71:437-439, 1994
  pubmed

• 44) Folsom AR, Nieto FJ, Sorlie P et al:Helicobacter pylori seropositivity and coronary heart disease incidence. Circulation 98:845-850, 1998
  pubmed

• 45) Strachan DP, Mendall MA, Carrington D et al:Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study. Circzalation 98:1286-1290, 1998
  pubmed

• 46) Pasceri V, Cammarota G, Patti G et al:Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97:1675-1679, 1998
  pubmed

• 47) Chiba S, Sugiyama T, Matsumoto H et al:Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain-Barre syndrome. Ann Neurol 44:686-688, 1998
  pubmed

P.134 掲載の参考文献

• 1) Satoh K, Kimura K, Taniguchi Y et al:Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 93:569-573, 1998
  pubmed

• 2) Rauws EAJ:Therapeutic attempts at eradication of Campylobacter pylori. Eur J Gastroenterol Hepatol 1:34-41, 1989

• 3) Kawanishi M, Fukuda S, Kawaguchi H et al:Significance of rapid urease test for identification of Helicobacter pylori in comparison with histological and culture studies. J Gastroenterol 30:16-20, 1995
  pubmed

• 4) Laine L, Suchower L, Johnson E et al:Accuracy of CLOtest after Helicobacter pylori therapy. Gastrointest Endosc 47:250-253, 1998
  pubmed

• 5) Murata H, Kawano S, Tsuji S et al:Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. Am J Gastroenterol 93:2102-2105, 1998
  pubmed

• 6) Nishikawa K, Sugiyama T, Kato M et al:A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and 13C-urea breath test. Gastrointest Endosc 51:164-168, 2000

• 7) Hui PK, Chan WY, Cheung PS et al:Pathologic changes of gastric mucosa colonized by Helicobacter pylori. Hum Pathol 23:548-556, 1992
  pubmed

• 8) Dixon MF, Genta RM, Yardley JH et al:Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161-1181, 1996
  pubmed

• 9) Loffeld RJ, Stobberingh E, Flendrig JA et al:Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified giemsa stain, and immunohistochemistry. A retrospective study. J Pathol 165:69-73, 1991
  pubmed

• 10) Christensen AH, Gjorup T, Hilden J et al:Observer homogeneity in the histologic diagnosis of Helicobacter pylori. Latent class analysis, kappa coefficient, and repeat frequency. Scnad J Gastroenterol 27:933-939, 1992

• 11) Shimizu T, Akamatsu T, Ota H et al:Immunohistochemical detection of Helicobacter pylori in the surface mucous gel layer and its clinicopathological significance. Helicobacter 1:197-206, 1996
  pubmed

• 12) Jonkers D, Stobberingh E, de Bruine A et al:Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies.J Infect 35:149-154, 1997
  pubmed

• 13) Marzio L, Angelucci D, Grossi L et al:Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy. Am J Gastroenterol 93:223-226, 1998
  pubmed

• 14) Iwaki H, Sugiyama T, Asaka M:Amodified McMullen's staining for Helicobacter pylori:a high-contrast, visibly prominent method. Helicobacter 3:45-48, 1998

• 15) Saito N, Sato F, Kato M et al:Detection of coccoid Helicobater pylori:light microscopical immunogold silver enhancing stain. Helicobacter 3:170-173, 1998

• 16) Kawakami Y, Akahane T, Gotoh A et al:Successful development of air-dried microplates (HP-Plates) for susceptibility testing against Helicobacter pylori isolates. Microbiol Immunol 41:703-708, 1997
  pubmed

• 17) Versalovic J, Fox JG:Helicobacter, In:Manual of Clinical Microbiology, 7th ed, ed by Murray PR, Baron EJ, Pfaller MA et al, ASM press, Washington DC, 1999, pp716-726

• 18) Graham DY, Klein PD, Evans DJ Jr et al:Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet i:1174-1177, 1987
  pubmed

• 19) Slomianski A, Schubert T, Cutler AF:13C-urea breath test to confirm eradication of Helicobacter pylori. Am J Gastroenterol 90:224-226, 1995
  pubmed

• 20) Kato M, Asaka M, Ohara S et al:Clinical studies of 13C-urea breath test in Japan. J Gastroenterol 33 (suppl 10):36-39, 1998

• 21) Miwa H, Ohkura R, Nagahara A et al:13C-urea breath test for assessment of cure of Helicobacter pylori infection at 1 month after treatment. J Clin Gastroenterol 27 (suppl 1):S150-S153, 1998

• 22) Ohara S, Kato M, Asaka M et al:The UBiT-100 13CO2 infrared analyzer:comparison between infrared spectrometric analysis and mass spectrometric analysis. Helicobacter 3:49-53, 1998
  pubmed

• 23) Ohara S, Kato M, Asaka M et al:Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 33:6-13, 1998
  pubmed

• 24) Corvaglia L, Bontems P, Devaster JM et al:Accuracy of serology and 13C-urea breath test for detection of Helicobacter pylori in Children. Pediatr Infect Dis J 18:976-979, 1999
  pubmed

• 25) Kato S, Ozawa K, Konno M et al:Diagnostic accuracy for the 13C-urea breath test for childhood Helicobacter pylori infection:a multicenter Japanese study. Am J Gastroenterol 97:1668-1673, 2002
  pubmed

• 26) Nagata K, Satoh H, Iwahi T et al:Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori:unique action selective for H pylori cells. Antimicrob Agents Chemother 37:769-774, 1993
  pubmed

• 27) Tsuchiya M, Imamura L, Park JB et al:Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 18:1053-1056, 1995
  pubmed

• 28) Chey WD:Proton pump inhibitors and the urea breath test:how long is long enough? Am J Gastroenterol 92:720-721, 1997

• 29) El-Nujumi A, Hilditch TE, Williams C et al:Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the 14C-urea breath test. Eur J Gastroenterol Hepatol 10:759-764, 1998
  pubmed

• 30) Connor SJ, Seow F, Ngu MC et al:The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects. Aliment Pharmacol Ther 13:1287-1293, 1999
  pubmed

• 31) Feldman RA, Deeks JJ, Evans SJ:Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobaeter pylori Serology Study Group. Eur J Clin Microbiol lnfect Dis 14:428-433, 1995

• 32) Loy CT, Irwig LM, Katelaris PH et al:Do commercial serological kits for Helicobacter pylori infection differ in accuracy?A meta-analysis. Am J Gastroenterol 91:1138-1144, 1996
  pubmed

• 33) Misawa K, Kumagai T, Shimizu T et al:A new histological procedure for re-evaluation of the serological test for Helicobacter pylori. Eur J Clin Microbiol Infect Dis 17:14-19, 1998
  pubmed

• 34) Miwa H, Kikuchi S, Ohtake K et al:Insufficient diagnostic accuracy of imported serological kits for Helicobacter pylori infection in Japanese population. Diagn Microbiol lnfect Dis 36:95-99, 2000

• 35) Hackelsberger A, Schultze V, Peitz U et al:Performance of a rapid whole blood test for Helicobacter pylori in primary care:a German multicenter study. Helicobacter 3:179-183, 1998

• 36) Chey WD, Murthy U, Shaw S et al:A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection:a United States, multicenter trial. Am J Gastroenterol 94:1512-1516, 1999

• 37) Wong BC, Wong W, Tang VS et al:An eveluation of whole blood testing for Helicobacter pylori infection in the Chinese Population. Aliment Pharmacol Ther 14:331-335, 2000

• 38) Katsuragi K, Noda A, Tachikawa T et al:Highly sensitive urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori 3:289-295, 1998
  pubmed

• 39) Miwa H, Hirose M, Kikuchi S et al:How useful is the detection kit for antibody to Helicobacter pylori in urine (URINELISA) in clinical practice?. Am J Gastroenterol 94:3460-3463, 1999
  pubmed

• 40) Luzza F, Imeneo M, Marasco A et al:Evaluation of a commercial serological kit for detection of salivary immunoglobulin G to Helicobacter pylori:a multicenter study. Eur J Gastroenterol Hepatol 12:1117-1120, 2000
  pubmed

• 41) Raymond J, Kalach N, Bergeret M et al:Evaluation of a serological test for diagnosis of Helicobacter pylori infection in children. Eur J Clin Microbiol Infect Dis 15:415-417, 1996
  pubmed

• 42) Corvaglia L, Bontems P, Devaster JM et al:Accuracy of serology and 13C-urea breath test for detection of Helicobacter pylori in children. Pediatr lnfect Dis 18:976-979, 1999
  pubmed

• 43) Malaty HM, Logan ND, Graham DY et al:Helicobacter pylori infection in asymptomatic children:comparison of diagnostic tests. Helicobacter 5:155-159, 2000
  pubmed

• 44) Cutler AF, Prasad VM:Long-term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 91:85-88, 1996
  pubmed

• 45) Ishizuka J, Sugiyama T, Okawahara T et al:Clinical evaluation of Helicobacter pylori stool antigen (HpSA) assay for assessment of diagnosis and eradication. Nippon Shokakibyo Zassi 96:196, 1999

• 46) Trevisani L, Sartori S, Galvani F et al:Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces:aprospective pilot study. Am J Gastroenterol 94:1830-1833, 1999

• 47) Ishihara S, Kaji T, Kawamura A et al:Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy. Aliment Pharmacol Ther 14:611-614, 2000
  pubmed

• 48) Ohkura R, Miwa H, Murai T et al:Usefulness of a novel enzyme immunoassay for the detection of Helicobacter pylori in feces. Scand J Gastroenterol 35:49-53, 2000
  pubmed

• 49) Vaira D, Malfertheiner P, Megraud F et al:Noninvasive antigen-based assay for assessing Helicobacter pylori eradication:a European multicenter study. The European Helicobacter pylori HpSA Study Group. . Am J Gastroenterol 95:925-929, 2000

• 50) Odaka T, Yamaguchi T, Koyama H et al:Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. Am J Gastroenterol 97:594-599, 2002
  pubmed

• 51) Kato S, Ozawa K Okuda M et al:Accuracy of the stool antigen test for the diagnosis of childhood Helicobacter pylori infection. a multicenter Japanese study. Am J Gastroenterol 98:296-300, 2003
  pubmed

• 52) Vaira D, Vakil N, Menegatti M et al:The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann 1ntern Med 136:280-287, 2003

P.139 掲載の参考文献

• 1) The European Helicobacter pylori Study Group (EHPSG):Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 41:8-13, 1997

• 2) Peura DA:The report of the Digestive Health Initiative international update conference on Helicobacter pylori. Gastroenterology 113:S4-S8, 1997

• 3) Murakami K, Fujioka T, Okimoto T et al:Drug combinations with amoxycillin reduce selection of clarithromycinresistance during. Helicobacter pylori eradication therapy.Int J Antimicrob 19:67-70, 2002

• 4) Lind T, Megraud F, Unge P et al:The MACH2 study:role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999
  pubmed

• 5) Miwa H, Ohkura R, Murai T et al:Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection . Aliment Pharmacol Ther 13:741-746, 1999
  pubmed

• 6) Asaka M, Sugiyama T, Kato M et al:Amulticenter, double-blind study on the triple therapy with lansoprazole/amoxycillin/clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 7) Kihara K, Satoh K, Sugano K et al:Rabeprazole, amoxycillin and low-or high-dose clarithromycin for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 14:1083-1087, 2000
  pubmed

• 8) Miwa H, Murai T, Sato K et al:Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazoleand amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol 35:536-539, 2000

• 9) Isomoto H, Furusu H, Morikawa T et al:5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillinfor Helicobacter pylori eradication. Aliment Pharmacol Ther 14:1619-1623, 2000
  pubmed

• 10) Ogura K, Yoshida H, Maeda S et al:Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given? Scand J Gastroenterol 36:584-588, 2001
  pubmed

• 11) 桑山肇, 吉田俊一, 中村武史ほか:オメプラゾール, アモキシシリン及びクラリスロマイシンの3剤療法によるHelicobacter Pylori除菌療法の第III相二重盲検試験. 第7回日本ヘリコバクター学会学術集会抄録集, 2001, p 155

• 12) Spinzi GC, Bierti L, Bortoli A et al:Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 12:433-438, 1998
  pubmed

• 13) Miwa H, Nagahara A, Sato K et al:Efficacy of l week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 14:317-321, 1999
  pubmed

• 14) Miwa H, Ohkusa R, Murai T et al:Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 3:132-138, 1998

• 15) Suzuki J, Mine T, Kobayasi I et al:Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 3:59-63, 1998
  pubmed

• 16) 柏原渉, 橋本明美, 高祐ほか:Helicobacter pylori除菌中に出血性腸炎をきたした一例. Helicobacter Research 2:580-581, 1998

• 17) 小林寅哲, 戸田陽代, 長谷川美幸ほか:胃潰瘍患者粘膜より分離したHelicobacter Pyloriの各種抗菌薬感受性. 日本化学療法学会雑誌 44:719-722, 1996

• 18) 村上和成, 藤岡利生:わが国におけるHelicobacter pylori除菌治療と薬剤耐性. Helicobacter Research 2:423-428, 1998
  Medical*Online

• 19) Kato M, Yamaoka Y, Kim JJ et al:Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44:2214-2216, 2000
  pubmed

• 20) Wurzer H, Rodrigo L, Stamler D et al:Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicated Helicobacter pylori and heals duodenal ulcer. Aliment Pharmacol Ther 11:934-952, 1997

• 21) Vakil N, Hahn B, McSorley D:Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 93:1423-1435, 1998

• 22) Adamek RJ, Suerbaum S, Phaffenbach B et al:Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin-influence on treatment outcome. Am J Gastroenterol 93:386-389, 1998
  pubmed

• 23) Nagahara A, Miwa H, Ohkura R et al:Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 115:613-618, 2001

• 24) ワークショップ4再除菌の方法 (臨床). 第5回日本ヘリコバクター学会学術集会抄録集, pp59-61, 1999

• 25) ワークショップ3 H. pylori除菌のsecond line therapy. 第6回日本ヘリコバクター学会学術集会抄録集, pp71-76, 2000

• 26) Murakami K, Sato R, Okimoto T et al:Efficacy of triple therapy comprising rabeprazole, amoxicillin, and metronidazole for second-line Helicobaeter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 17:119-123, 2003
  pubmed

• 27) Alarcon T, Domingo D, Lopez-Brea M:Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 12:19-26, 1999

• 28) Beard RN, Noller KL, O'Fallon WM et al:Cancer after exposure to metronidazole. Mayo Clin Proc 63:147-153, 1988

• 29) Friedman GD, Selby JV:Metronidazole and cancer. JAMA 261:866, 1989
  pubmed

• 30) 山本達男, 種池郁恵, 合志聡ほか:メトロニダゾールについて (耐性・発癌性など) . 日本ヘリコバクター学会誌 4:30-33, 2002
  Medical*Online

• 31) Kihira K, Satoh K, Saifuku K et al:Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 11:511-514, 1997
  pubmed

• 32) Takimoto T, Satoh K, Taniguchi Y et al:The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. Helicobacter 2:86-91, 1997
  pubmed

• 33) 佐藤竜吾, 久保田利博, 村上和成ほか:Helicobacter pylori除菌後の問題点. 日本内科学会雑誌87:881-885, 1998

• 34) 塩谷昭子, 西岡新吾:H. pylori除菌後にみられる食道炎, 胃炎, 十二指腸炎の発生. 日本臨牀57:191-195, 1999

• 35) Hamada H, Haruma K, Mihara M et al:High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori:impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 14:729-735, 2000
  pubmed

• 36) 飯島克則, 大原秀一, 関根仁ほか:H. Pyloriua除菌後に経験される「逆流性食道炎」,「十二指腸びらん」の発生病理-特に酸分泌能変化との関連について. 日本臨牀 57:196-200, 1999

• 37) 金児泰明, 松澤正浩, 中村直ほか:H. pylori除菌治療後に生ずる上部消化管病変の予防対策と治療. 日本臨牀 57:208-211, 1999
  Medical*Online

• 38) 加藤元嗣, 穂刈格, 杉山敏郎ほか:H. pylori除菌と胃・食道逆流症. 日本内科学会雑誌 89 98-103, 2000

• 39) 桜井宏一, 高橋寛, 渥美節子ほか:Helicobacter pylori除菌療法後に発症した食道炎の検討. Prog Dig Endosc 51:59-62, 1997

• 40) Malfertheiner P, Megraud F, Omorain C et al:Current concepts in the management of Helicobacter pylori infection-The Maastrictht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180, 2002
  pubmed

• 41) 菱木智, 志和忠志, 横山知子ほか:心血管系疾患の危険因子に対するHelicobacter pylori 除菌治療の影響. 日本消化器病学会雑誌 98:814-821, 2001
  Medical*Online